Effect of Sharbat-e-Deenarin uncomplicated Pelvic Inflammatory Disease- A Clinical study

Pelvic inflammatory disease (Waram al-Rahim)is one of the most serious gynaecological infections of the upper female genital tract with the worldwide annual rate of 10-20/1000 women of reproductive age.  The objective planned for the study was to evaluate the effect of Sharbat-e-Deenar in uncomplicated Pelvic Inflammatory Disease (uPID).  A pre and post observational single group clinical study was carried out in the Department of IlmulQabalatwaAmrazeNiswan, National Institute of Unani Medicine, Hospital, Bengaluru. Diagnosed cases (n=30) of uPID were included in the study. Patients with complicated PID, history of antibiotic therapy within seven days of recruitment; delivery, abortion or gynecologic surgery within the last 30 days,  systemic diseases, malignancies, pregnancy & lactation were excluded. Sharbat-e-Deenarconsists of Poste baikhekasniandTukhmekasni(Cichorium intybus  Linn.), Gulesurkh (Rosa damascene mill.), Tukhmekasoos(CuscutareflexaRoxb.)  and Rewandchini (Rheum emodiWall. ex Meissn) were administered orally in a dose of 20 ml twice daily for 14 days. Outcome measures were 30-70% clinical improvement in Visual Analogue Scale (VAS) score for lower abdominal pain and McCormack Pain Scale (McPS) score for abdominopelvic tenderness and White Blood Cells (WBCs) count <10 on saline microscopy of discharge. Data were analyzed using paired Student ‘t’ test, Wilcoxon Signed rank test and Paired Proportion test.Clinical improvement of 30-70% in McPS and VAS score was achieved in 96.7% (p<0.001**) and 93.3% (p<0.001**) patients respectively. WBCs count <10 on saline microscopy of discharge was achieved in 70% patients (p<0.001**).Sharbat-e-Deenarwas effective in improving the sign & symptoms of PID due to its anti-microbial, anti-inflammatory, anti-spasmodic and anti-oxidant properties. No adverse effect of the research drug was encountered during the study. Hence, Sharbat-e-Deenar serves as an effective alternative in patients with PID, proving the research hypothesis.